PCV13 vaccine is effective against serotype 3 invasive pneumococcal disease in children

Objectives:
The 13-valent pneumococcal conjugate vaccine (PCV13) is the only licensed PCV with serotype 3 polysaccharide in its formulation. Post-licensure PCV13 effectiveness studies against serotype 3 invasive pneumococcal disease (IPD) in children have shown inconsistent results. Therefore, this review article has been conducted.

Is 13-valent pneumococcal conjugate vaccine (PCV13) effective against serotype 3 invasive pneumococcal disease in children?

Study design:
This review article included 4 published observational studies and 2 conference posters that provided PCV13 vaccine effectiveness (VE) estimates stratified by serotype.

Results and conclusions:
The investigators found in random effects meta-analysis that pooled PCV13 vaccine effectiveness against serotype 3 invasive pneumococcal disease was 63.5% [95% CI = 37.3-89.7].

The investigators found sensitivity analysis including conference posters gave PCV13 vaccine effectiveness against serotype 3 invasive pneumococcal disease of 72.4% [95% CI = 56.7-88.0].

The investigators found pooled data from case-control studies with similar methodologies and high quality supported direct PCV13 protection against serotype 3 invasive pneumococcal disease in children.

The investigators concluded that 13-valent pneumococcal conjugate vaccine (PCV13) is effective against serotype 3 invasive pneumococcal disease in children.

Original title:
Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Invasive Disease Caused by Serotype 3 in Children: A Systematic Review and Meta-Analysis of Observational Studies by Sings HL, De Wals P, [...], Jodar L.

Link:
https://www.ncbi.nlm.nih.gov/pubmed/30357326

Additional information of El Mondo:
Find more information/studies on food fortification/malnutrition and vaccination right here.